
Swiss biotech company Numab has received a capital injection for the further development of its main candidate for treating a series of cancer diseases.
Numab has secured CHF 100m (USD 111m) in a series C capital raising round co-led by Novo Holdings and HBM Partners.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app